Authors: RAU R SANDER O DENBROEDER A VANRIEL PLCM VANDERPUTTE L KRUGER K SCHATTENKIRCHER M FENNER H LASSMANN A KUPPER H KEMPENI J

Citation: R. Rau et al., LONG-TERM EFFICACY AND TOLERABILITY OF MULTIPLE IV DOSES OF THE FULLYHUMAN ANTI-TNF-ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID-ARTHRITIS, Arthritis and rheumatism, 41(9), 1998, pp. 137-137

Authors: VANDEPUTTE LBA VANRIEL PLCM DENBROEDER A SANDER O RAU R BINDER C KRUGER K SCHATTENKIRCHER M FENNER H SALFELD J BANKMANN Y KUPPER H KEMPENI J

Citation: Lba. Vandeputte et al., A SINGLE-DOSE PLACEBO-CONTROLLED PHASE-1 STUDY OF THE FULLY HUMAN ANTI-TNF ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID-ARTHRITIS, Arthritis and rheumatism, 41(9), 1998, pp. 148-148

Authors: SANDER O DENBROEDER A VANDERHOOGEN F LAAN R VANDEPUTTE L RAU R

Citation: O. Sander et al., 30 MONTHS OF TREATMENT WITH A TNF-ALPHA RECEPTOR-FUSION PROTEIN (TNFR55-IGG1, RO-45-2081) IN PATIENTS WITH SEVERE REFRACTORY RA, Arthritis and rheumatism, 40(9), 1997, pp. 301-301